A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 4, 2002, Pages 589-599

  Algar, Elizabeth ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL LEUKEMIA; CANCER GENETICS; CELL DIFFERENTIATION; CELL LINEAGE; GENE; GENE EXPRESSION; GENE MUTATION; HEMATOPOIESIS; HUMAN; LEUKEMIA; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; WT1 GENE;

HEMATOPOIESIS; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA; LEUKEMIA, B-CELL; TUMOR CELLS, CULTURED; WILMS TUMOR; WT1 PROTEINS;

EID: 0036323565     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160260194749     Document Type: Review

References (99)

1. Isolation and characterization of a zinc-finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
2. Homozygous deletion in Wilms' tumors of a zinc-finger gene identified by chromosome jumping
3. Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with "zinc-binding finger" structure
4. Alternative splicing and genomic structure of the Wilms' tumor gene WT1
5. RNA editing in the Wilms' tumor susceptibility gene WT1
6. A non-AUG translation initiation codon event generates novel WT1 isoforms
7. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties
8. The Wilms tumor gene product WT1 activates or suppresses transcription through separate functional domains
9. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes
10. RNA binding by the Wilms tumor suppressor zinc-finger proteins
11. An RNA recognition motif in Wilms tumor protein (WT1) revealed by structural modeling
12. Smallest region of overlap in Wilms tumor deletions implicates an 11p13 zinc-finger gene as a disease locus
13. Evidence for WT1 as a Wilms tumor gene: Intragenic germinal deletion on a bilateral WT
14. Structural rearrangements of the WT1 gene in Wilms tumor cells
15. Intragenic homozygous deletion of the WT1 gene in Wilms tumour
16. Zinc-finger point mutations within the WT1 gene in Wilms' tumour patients
17. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology
18. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' Tumour with high levels of expression of a truncated transcript
19. Transcriptional repression mediated by the WT1 Wilms tumor gene product
20. DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1
21. Differential effects of Wilms tumor WT1 splice variants on the Insulin receptor promoter
22. The Wilms tumor gene, WT1 is negatively autoregulated
23. Differential regulation of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation
24. Regulation of insulin-like growth factor 1 receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor
25. Increases expression of the insulin-like growth factor 1 receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product
26. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis
27. Repression of the transforming growth factor-beta 1 gene by the Wilms tumor suppressor WT1 gene product
28. WT1 modulates apoptosis by transcriptionally upregulating the BCL-2 protooncogene
29. The Wilms tumor gene product WT1, represses transcription of the platelet-derived growth factor A-chain gene
30. Inhibition of the colony stimulating factor-1 promoter activity by the product of the Wilms' tumor locus
31. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin
32. E-Cadherin is a WT1 target gene
33. Regulation of ornithine decarboxylase gene expression by the Wilms tumor suppressor WT1
34. Induction of p21 by the Wilms' tumor suppressor gene WT1
35. The Wilms tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene
36. The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation
37. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing
38. Presence of WT1, the Wilms tumor suppressor gene product, in nuclear poly(A)+ ribonucleoprotein
39. A clinical overview of WT1 gene mutations
40. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome
41. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion
42. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations
43. Donor splice-site mutations in WT1 are responsible for Frasier syndrome
44. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms
45. The same mutation affecting splicing of the WT1 gene is present on Frasier syndrome patients with or without Wilms tumor
46. Frasier and Denys-Drash syndromes: Different disorders or part of a spectrum?
47. Wilms' tumor 1 and Dax 1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression
48. Two splice variants of the Wilms tumor 1 gene have distinct functions during sex determination and nephron formation
49. WT-1 is required for early kidney development
50. Yac complementation shows a requirement for Wt1 in the development of the epicardium, adrenal gland and throughout nephrogenesis
51. The Wilms tumor suppressor gene wt1 is required for development of the spleen
52. The expression of the Wilms tumor gene WT1 in the developing mammalian embryo
53. Expression of the Wilms tumor gene (WT1) in human leukemias
54. Expression of the candidate Wilms tumor gene, WT1, in human leukemia cells
55. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
56. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
57. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: Importance of the monitoring of minimal residual disease by WT1 assay
58. Monitoring of WT-1 gene expression in peripheral blood of patients with acute leukemia by semiquantitative RT-PCR: Possible marker for detection of minimal residual leukemia
59. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes
60. Detection of WT1 transcript by RTPCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia
61. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia
62. Aberrant overexpression of the Wilms' tumour gene (WT1) in human leukemia
63. WT1 contributes to leukemogenesis: Expression patterns in 7,12,dimethylbenz(a)anthracene (DMBA)-induced leukemia
64. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene product
65. Cancer immunotherapy targeting Wilms' tumor gene WT1 product
66. HLA class 1-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
67. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
68. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
69. Expression of the Wilms' tumor gene WT1 in normal hematopoiesis
70. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow
71. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth
72. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines
73. Growth inhibition of human leukaemic cells by WT1 (Wilms' tumour gene) antisense oligonucleotides: Implications for the involvement of WT1 in leukaemogenesis
74. Physical and functional interaction between WT1 and p53 proteins
75. A novel repressor PAR4 modulates transcription and growth suppression functions of the Wilms' tumour suppressor, WT1
76. Inhibition of cellular proliferation by the Wilms' tumor suppressor, WT1, requires association with the inducible chaperone Hsp70
77. Molecular cloning of the cDNA and chromosomal localization of the gene for human ubiquitin-conjugating enzyme 9
78. Ciao1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1
79. Regulation of WT1 by phosphorylation: Inhibition of DNA binding, alteration of transcriptional activity and cellular translocation
80. Inhibition of DNA binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc-finger domain
81. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells
82. Wilms' tumour gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells
83. Down-regulation of Wilms tumor gene (wt1) during myelomonocytic differentiation in HL-60 cells
84. The Wilms tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro
85. Overexpression of murine wt1 +/+ and -/- isoforms has no effect on chemoresistance but delays differentiation in the K562 leukaemia cell line
86. Constitutive expression of the Wilms' tumour gene (WT1) in the leukaemic cell line U937 blocks part of the differentiation program
87. Wilms' tumour gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain
88. Wilms' tumour gene (WT1) competes with differentiation-inducing signal in haematopoietic progenitor cells
89. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)
90. Expression of the Wilms' tumour suppressor gene 1 (WT1) is upregulated by Leukaemia Inhibitory Factor and induces monocytic differentiation in M1 leukaemic cells
91. The Wilms tumor suppressor WT1 directs stage specific quiescence and differentiation of human hematopoietic progenitor cells
92. The Wilms tumor (WT1) gene is mutated in a secondary leukemia in a WAGR patient
93. Mutations in the Wilms' tumour gene WT1 in leukaemias
94. Mutation analysis of the WT1 gene in sporadic childhood leukaemia
95. WT1 mutations occur mainly in Acute Myeloid Leukaemia and may confer drug resistance
96. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies
97. Dominantnegative mutations of the Wilms' tumor predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukemia
98. Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control
99. The Wilms tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter